提高投资者回报 研发管线潜在价值凸显 根据公司业绩快报，公司全年实现基本每股收益0.74元，同比增长15.63%，实现企业对投资者回报的提 高。 本报讯 （记者袁传玺）天士力2025年加入华润体系后首年融合业绩超出市场预期。2月6日晚间，天士 力发布的2025年业绩快报显示，公司2025年实现营业总收入82.36亿元；实现归属于上市公司股东的净 利润11.05亿元，同比增加15.68%。 融入华润体系推动提质增效 据悉，天士力作为华润三九"一体两翼"战略中的"一翼"，核心定位为"创新驱动"。天士力正全面推进与 华润三九的首年融合工作，从"价值重塑"、"业务重塑"、"组织重塑"和"精神重塑"四个维度系统化升级 管理体系，实现强强联合的战略协同。 公司在融入华润体系的同时，进行组织和运营管理等各个方面的优化，逐步提升公司经营资产的质量。 申万宏源证券的研报指出，华润三九将借助其在管理、渠道、产业方面的资源，为公司进一步赋能，促 进协同效应，提升天士力的竞争优势。在运营管理方面，公司积极落实华润管理理念，加强财务、人力 资源、EHSQ及大监督体系的融合，开展"焕新增效"等系列组织优化活动，优化运营管控模式，提升管 ...

转自：新华财经 •李强主持召开国务院常务会议 研究促进有效投资政策措施 •虚拟货币监管再升级 人民银行等八部门联合印发通知 重申虚拟货币相关业务活动属于非法金融活动 •预制菜将迎首个国标 重点从食品安全和营养健康方面对预制菜作出规定 •国务院总理李强2月6日主持召开国务院第十次全体会议，讨论拟提请十四届全国人大四次会议审议的政府工作报告稿和"十五五"规划纲要草案稿。李强指 出，要坚持远近结合，扎实推动高质量发展。进一步加强年度工作和五年规划的衔接，将中长期目标任务落实到年度工作部署中。要注重整体规划和重点突 破相结合，围绕规划纲要高质量编制各领域专项规划，深入谋划实施一批重大举措、重大项目，特别是要在发展新质生产力、做强国内大循环、促进居民增 收等方面取得更大突破。要注重前瞻布局，坚持脚踏实地，在实践中不断塑造引领未来的发展新优势。（新华社） •国务院总理李强2月6日主持召开国务院常务会议，研究促进有效投资政策措施。会议指出，促进有效投资对于稳定经济增长、增强发展后劲具有重要作 用。要创新完善政策措施，加力提效用好中央预算内投资、超长期特别国债、地方政府专项债券等资金和新型政策性金融工具。要结合制定实施"十五 ...

Group 1 - The company, Tianjin Tasly Pharmaceutical Co., Ltd., has signed a termination agreement with Arbor Pharmaceuticals, LLC, due to Arbor's acquisition by Azurity Pharmaceuticals, Inc. The termination was mutually agreed upon after discussions between both parties [2][4]. - The company received a total of $7.5 million as part of the termination agreement, which includes milestone payments and commercialization royalties related to the T89 product in the U.S. market [2][6]. - The termination of the agreement will not have a significant impact on the company's project advancement, production operations, or financial status. The company will continue to manage the termination-related matters appropriately [6]. Group 2 - In 2025, the company officially became part of China Resources Sanjiu, completing a "100-day integration" and steadily promoting the "first-year integration" efforts. The focus remains on stabilizing business, teams, and clients while enhancing efficiency and competitiveness [8]. - The company reported a total revenue of 8.236 billion yuan for 2025, a decrease of 3.08% year-on-year, while the net profit attributable to shareholders increased by 15.68% to 1.105 billion yuan. The decline in revenue is primarily attributed to a 14.24% decrease in pharmaceutical commercial income due to industry policy impacts [8].

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. reported a mixed performance for the year 2025, with a decline in total revenue but an increase in net profit, highlighting the impact of industry policies on its business operations [1][3]. Financial Performance Summary - Total revenue for 2025 was 8.236 billion yuan, a decrease of 3.08% compared to the previous year [2]. - Net profit attributable to shareholders was 1.105 billion yuan, an increase of 15.68% year-on-year [2]. - Non-recurring net profit attributable to shareholders was 787 million yuan, down 24.06% year-on-year [2]. - Basic earnings per share increased to 0.74 yuan, up 15.63% from 0.64 yuan [2]. - The weighted average return on equity rose to 9.07%, an increase of 1.39 percentage points [2]. Asset and Equity Summary - Total assets at the end of 2025 were 153.42 billion yuan, a 2.44% increase from the beginning of the year [2]. - Shareholders' equity attributable to the listed company was 124.02 billion yuan, up 4.19% [2]. - The net asset per share attributable to shareholders increased to 8.30 yuan, a rise of 4.14% [2]. Business Segment Insights - The decline in revenue was primarily attributed to a 14.24% decrease in pharmaceutical commercial income, particularly from chain pharmacy operations, due to industry policies such as "outpatient overall planning" [3]. - The pharmaceutical commercial segment reported a significant revenue drop of 16.70% in the first three quarters of 2025 compared to the same period in 2024 [4]. Control Change and Market Performance - In 2025, the control of the company changed significantly, with China Resources Sanjiu directly holding 28% of the shares, marking a shift in the controlling shareholder from Tasly Group to China Resources Limited [5]. - As of February 6, 2025, the company's stock price was 15.09 yuan per share, with a total market capitalization of 22.544 billion yuan [5].

Investment Announcements - Jinghe Integrated plans to invest 2 billion yuan to acquire 100% equity of Jingyi Integrated, which is the main body of its fourth phase project with a total investment of 35.5 billion yuan, focusing on 12-inch wafer manufacturing lines and targeting applications in OLED displays, AI smartphones, and smart vehicles [2] - Wantong Expressway intends to invest approximately 5.42 billion yuan in the renovation and expansion project of Lianhuo Expressway, with construction expected to start in 2026 and complete by 2029 [10] - Yiwang Yichuang plans to acquire 100% equity of Lianshi Legend, an AI algorithm-based intelligent marketing service provider, through a combination of share issuance and cash payment [4] Equity Investments - Lvtong Technology's industrial fund plans to invest 10 million yuan in Shenghao Optoelectronics, which specializes in optical communication chip testing equipment [3] - Dayu Water plans to transfer 28.5% equity of Huitu Technology for 192 million yuan, reducing its stake from 55.10% to 26.60% [6] - Xinzhi Group intends to invest in a factory project for rotor cores in Thailand, with a total investment of 40 million USD [8] Performance Reports - Huaren Sanjiu reported a net profit of 3.422 billion yuan for 2025, a year-on-year increase of 1.6%, with total revenue of 31.629 billion yuan, up 14.53% [17] - Longyuan Power achieved a power generation volume of 7.1627 million MWh in January 2026, a year-on-year increase of 12.05% [18] - Zhongchuan Special Gas reported a net profit of 347 million yuan for 2025, a year-on-year increase of 12.92% [19] Legal and Regulatory Updates - Aier Eye Hospital clarified that Xiangyang Hengtai Kang is not affiliated with it, addressing media reports linking the two [2] - Yihua Group announced that its subsidiary reached a settlement in a lawsuit involving over 2.314 billion yuan [11] - Tian Sheng New Materials received a notice from the China Securities Regulatory Commission regarding an investigation into information disclosure violations [13] Market Movements - Hu Silicon Industry's second-largest shareholder plans to reduce its stake by up to 3% [28] - Perfect World’s actual controller reduced his stake by 32.9793 million shares, accounting for 1.70% of the total share capital [29] - Dajiayikang's controlling shareholder plans to reduce its stake by up to 3% [32]

Core Viewpoint - China Resources Pharmaceutical (03320) reported preliminary unaudited financial data for Tianjin Tasly Pharmaceutical (600535) for the year ending December 31, 2025, indicating a decline in total operating revenue while showing an increase in net profit attributable to shareholders [1] Financial Performance - Total operating revenue for Tianjin Tasly Pharmaceutical reached RMB 8.236 billion, representing a year-on-year decrease of 3.08% [1] - Net profit attributable to shareholders amounted to RMB 1.105 billion, reflecting a year-on-year increase of 15.68% [1] Revenue Breakdown - The decline in operating revenue is primarily attributed to a 14.24% decrease in pharmaceutical commercial revenue, mainly from the chain pharmacy business, influenced by industry policies such as "outpatient overall planning" [1]

智通财经APP讯，华润医药(03320)发布天士力医药截至2025年12月31日止年度的未经审核初步财务资 料，天士力医药实现总营业收入人民币82.36亿元，同比下降3.08%，实现归属于上市公司股东的净利润 人民币11.05亿元，同比增长15.68%。从变动幅度上看，公司营业收入同比下降的主要原因是医药商业 收入(主要为连锁药店业务)受"门诊统筹"等行业性政策的影响同比减少14.24%。 ...

北京商报讯（记者 丁宁）2月6日晚间，天士力（600535）发布2025年度业绩快报显示，公司2025年实 现营业收入82.36亿元，同比下降3.08%；归属净利润11.05亿元，同比增长15.68%。 天士力表示，从变动幅度上看，公司营业收入同比下降的主要原因是医药商业收入（主要为连锁药店业 务）受"门诊统筹"等行业性政策的影响同比减少14.24%。 ...

Group 1 - The company announced a projected operating revenue of 8.236 billion yuan for 2025, representing a year-on-year decrease of 3.08% [2] - The net profit attributable to shareholders of the listed company is expected to be 1.105 billion yuan, reflecting a year-on-year increase of 15.68% [2]

每经AI快讯，天士力2月6日晚间发布2025年度业绩快报，营业收入约82.36亿元，同比减少3.08%；归属 于上市公司股东的净利润约11.05亿元，同比增加15.68%；基本每股收益0.74元，同比增加15.63%。 每经头条（nbdtoutiao）——目标是囤700吨黄金！连续两年增持黄金最多的央行宣布：再买150吨 每日经济新闻 （记者 胡玲） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 ...